Oncology ASCO 2026: Are radiopharmaceuticals being systematically und... The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.
Oncology Why is pharma going gaga for radiopharmaceuticals? The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage.
Oncology Closing the global evidence gap in oncology, with Flatiron H... Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.